Literature DB >> 9920816

Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties?

H Brurok1, J H Ardenkjaer-Larsen, G Hansson, S Skarra, K Berg, J O Karlsson, I Laursen, P Jynge.   

Abstract

Manganese dipyridoxyl diphosphate (MnDPDP) is a contrast agent for magnetic resonance imaging (MRI) of the liver. Aims of the study were to examine if MnDPDP possesses superoxide dismutase (SOD) mimetic activity in vitro, and if antioxidant protection can be demonstrated in an ex vivo rat heart model. Superoxide (*O-2) and hydroxyl radicals (*OH-) were generated in xanthine oxidase and Fenton reactions. Spin adducts with 5,5-dimethyl-1-pyrroline-N-oxide were detected by electron spin resonance spectroscopy. Contractile function and enzyme release were monitored in rat hearts during hypoxia-reoxygenation. Low microM concentrations of MnDPDP and its metabolite Mn dipyridoxyl ethylene-diamine (MnPLED) dismutated *O-2, but showed no activity in Fenton or catalase reactions. MnDPDP 30 microM improved contractile function and reduced enzyme release in rat hearts during reoxygenation. It is concluded that MnDPDP and MnPLED possess SOD mimetic activities and may thereby protect the heart in oxidative stress. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920816     DOI: 10.1006/bbrc.1998.0131

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.

Authors:  Jan Olof G Karlsson; Karin Adolfsson; Bo Thelin; Per Jynge; Rolf Gg Andersson; Ursula G Falkmer
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

2.  Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Authors:  Tino Kurz; Derek Grant; Rolf Gg Andersson; Robertson Towart; Michelandrea De Cesare; Jan Olof G Karlsson
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

3.  Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.

Authors:  Jan Olof G Karlsson; Tino Kurz; Susanne Flechsig; Jacques Näsström; Rolf Gg Andersson
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 4.  Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Authors:  Jan Olof G Karlsson; Rolf Gg Andersson; Per Jynge
Journal:  Transl Oncol       Date:  2017-06-29       Impact factor: 4.243

Review 5.  Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration.

Authors:  Ryan A Cloyd; Shon A Koren; Jose F Abisambra
Journal:  Front Aging Neurosci       Date:  2018-12-13       Impact factor: 5.750

6.  Letter in response to: "Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial".

Authors:  Jan Olof G Karlsson; Per Jynge; Ingemar Lundström; Louis J Ignarro
Journal:  Trials       Date:  2019-06-24       Impact factor: 2.279

7.  Pretreatment with mangafodipir improves liver graft tolerance to ischemia/reperfusion injury in rat.

Authors:  Ismail Ben Mosbah; Yann Mouchel; Julie Pajaud; Catherine Ribault; Catherine Lucas; Alexis Laurent; Karim Boudjema; Fabrice Morel; Anne Corlu; Philippe Compagnon
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

8.  Oxidant Stress and Acetaminophen Hepatotoxicity: Mechanism-Based Drug Development.

Authors:  Anup Ramachandran; Hartmut Jaeschke
Journal:  Antioxid Redox Signal       Date:  2021-07-07       Impact factor: 7.468

Review 9.  MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue.

Authors:  Per Jynge; Arne M Skjold; Ursula Falkmer; Rolf G G Andersson; John G Seland; Morten Bruvold; Viggo Blomlie; Willy Eidsaunet; Jan O G Karlsson
Journal:  Contrast Media Mol Imaging       Date:  2020-09-04       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.